Not traditional prognostic factors in human conventional renal carcinoma

Minerva Urologica e Nefrologica

Volumn 53, Issue 4, 2001, Pages 211-219

  Cindolo, L ^a   Cantile, M ^a   Galasso, R ^a   Marsicano, M ^a   Napodano, G ^a   Altieri, V ^a  

^a NONE

Author keywords

Biological markers; Kidney neoplasms, diagnosis; Prognosis

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; HUMAN; KIDNEY NEOPLASMS; PROGNOSIS;

EID: 0035651289     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Reuter VE, Gaudin PB. Diagnostic surgical pathology. 3rd edition. Philadelphia: Lippincott Williams & Wilkins, 1999:1785-805.
2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408.
3. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Members of the Cancer Committee (review) Arch Pathol Med 1995;119:1109-12.
4. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993;68(1):4-17.
5. Steinbach F, Tanabe K, Alexander J, Edinger M, Tubbs R, Brenner W et al. The influence of cytokines on the adhesion of renal cancer cells to endothelium. J Urol 1996;155:743-8.
6. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-8.
7. Hoffmann R, Franzke A, Buer J, Sell S, Oevermann K, Duensing A et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 1999;79:1742-5.
8. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
9. Blay JY, Schemann S, Favrot MC. Local production of interleukin 6 by renal adenocarcinoma in vivo. J Natl Cancer Inst 2 1994;86(3):238.
10. Gogusev J, Augsti M, Chretien Y, Droz D. Interleukin-6 and TNF alpha production in human renal cell carcinoma. Kidney Int 1993;44(3):585-92.
11. Dosquet C, Schaetz A, Faucher C, Lepage E, Wautier JL, Richard F et al. Tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994;30A(2):162-7.
12. Hahannan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64.
13. Grankvist K, Ljungberg B, Rasmuson T. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer (Pred Oncol) 1997;74:233-6.
14. Clements J, Ward G, Kaushal A, Hi SI, Kennen C, Nicol D. A prostate-specific antigen-like protein associated with renal cell carcinoma in women. Clin Cancer Res 1997;3(8):1427-31.
15. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998;5(5):418-22.
16. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999;162(6):1934-7.
17. Masuda H, Kurita Y, Suzuki K, Fujiita K, Aso Y. Predictive value of serum immunosuppressive acidic protein for staging renal cell carcinoma : comparison with other tumour markers. Br J Urol 1997;80:25-9.
18. Partin AW, Criley SR, Steiner MS, Hsieh K, Simon JW, Lumadue J et al. Serum ferritin as a clinical marker for renal cell carcinoma : influence of tumor volume. Urology 1995;45(2):211-7.
19. Essen A, Ozen H, Ayhan A, Ergen A, Tasar C, Remzi F. Serum ferritin: a tumor marker for renal cell carcinoma. J Urol 1991;145(6):1134-7.
20. Kirkali Z, Guzelsoy M, Mungan MU, Kirkali G, Yorukoglu K. Serum ferritin as a clinical marker for renal cell carcinoma : influence of tumor size and volume. Urol Int 1999;62(1):21-5.
21. Ozen H, Uygur C, Sahin A, Tekgul S, Ergen A, Remzi D. Clinical significance of serum ferritin in patients with renal cell carcinoma. Urology 1995;46(4):494-8.
22. Srigley JR, Hutter RVP, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM. Current prognostic factors - renal cell carcinoma. Cancer 1997;80(5):994-6.
23. Morell-Quadreny L, Clar-Blanch F, Fennollosa-Enterna B, Perez-Bacete M, Martinez-Lorente A, Llombart-Bosch A. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res 1998;18:677-82.
24. Renshaw AA, Loughlin KR, Dutta A. Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms. Mod Pathol 1998;11(10):963-6.
25. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K. Prognostic value of Ki67 expression in renal cell carcinomas. Eur Urol 1997;31:350-5.
26. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996;77(1):164-71.
27. Yasunaga Y, Shin M, Miki T, Okuyama A, Aozasa K. Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 1998;68:11-8.
28. Papadopoulos I, Weichert-Jacobsen K, Wacker HH, Sprenger E. Correlation between DNA ploidy, proliferation marker Ki67 and early tumor progression in renal cell carcinoma. Eur Urol 1997;31:49-53.
29. Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer 1997;80(9):1768-75.
30. Ruiz-Cerdà JL, Hernandez M, Gomis F, Vera CD, Kimler BF, O'Connor JE et al. Value of deoxiribonucleic acid polidy and nuclear morphometry for prediction of disease progression in renal cell carcinoma. J Urol 1996;155:459-65.
31. Schafhauser W, Liedl T, Elsasser D, Zorcher T, Schrott KM. Flow cytometric analysis of DNA-aneuploidy subgroups and proliferation in renal cell carcinoma. Anticancer Res 1999;19(2C):1471-5.
32. Eskelinen M, Lipponen P, Nordling S: Prognostic evaluation of DNA flow cytometry and histo-morphological criteria in renal cell carcinoma. Anticancer Res 1995;15(5B):2279-83.
33. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994;7(7):766-70.
34. Gelb AB. Renal cell carcinoma - Current prognostic-factors. Cancer 1997;80(5):981-6.
35. Haitel A, Wiener HG, Blaschitz U, Marberger M, Susani M: Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type. Cancer 1999;85(7):1593-8.
36. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K, Kosma VM. Expression of cyclins A and D and p21 (waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 1999;80(12):2001-7.
37. Kawasaki T, Bilim V, Takahashi K, Tomita Y. Infrequent alteration of p53 pathway in metastatic renal cell carcinoma. Oncol Rep 1999;6(2):329-33.
38. Huang A, Fone PD, Gandour-Edwards R, White RW, Low RK. Immunohistochemical analysis of Bcl-2 protein expression in renal cell carcinoma. J Urol 1999;162(2):610-3.
39. Sejima T, Miyagawa I. Expression of bcl-2, p53 oncoprotein and proliferating cell nuclear antigen in renal cell carcinoma. Eur Urol 1999;35(3):242-8.
40. Vasavacla SP, Novick AC, Williams BR: P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;5(6):1057-61.
41. Lakshmanan Y, Subong EN, Partin AW. Differential nuclear matrix protein expression in prostate cancers : correlation with pathologic stage. J Urol 1998;159(4): 1354-8.
42. Alberti I, Parodi S, Barboro P, Sanna P, Nicolo G, Allera C et al. Differential nuclear matrix-intermediate filament expression in human prostate cancer in respect to benign prostatic hyperplasia. Cancer Lett 1996; 3;109(1-2):193-8.
43. Konety BR, Nangia AK, Nguyen TS, Veitmeier BN, Dhir R, Acierno JS et al. Identification of nuclear matrix protein alterations associated wih renal cell carcinoma. J Urol 1999;159(4):1359-63.
44. Nakagawa Y, Tsumatani K, Kuramatani N, Cho M, Kitahori Y, Konishi N et al. Prognostic value of nm23 protein expression in renal cell carcinomas. Oncology 1998;55(4):370-6.
45. Ljungberg B, Osterdahl B, Mehle C. Clinical significance of nm23 expression in renal cell carcinoma. Urol Res 1999;27(2):103-7.
46. Gilcrease M Z, Guzman-Paz M, Niehans G, Cerwitz D, McCarthy JB, Albores-Saavedra J: Correlation of CD44s expression in renal clear cell carcinomas with subsequent tumor progression or reccurrence. Cancer 1999;186(11):2320-6.
47. Hara I, Miyake H, Yamanaka K, Hara S, Arakawa S, Kamidono S: Expression of CD44 adhesion molecules in nonpapillary renal cell carcinoma and normal kidneys. Urology 1999;54(3):562-6.
48. Paradis V, Ferlicot S, Ghannam K, Zeimoura L, Blanchet P, Eschwege P et al. CD44 is an indipendent prognostic factor in convention renal cell carcinomas. J Urol 1999;161(6):1984-7.
49. Fischer C, George C, Kraus S, Terpe HJ, Luedecke G, Weidner W. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res 1999;19(2C):1513-7.
50. Avner ED. Polypeptide growth factors and the kidney: a developmental perspective. Pediatr Nephrol 1990;4(4): 345-53.
51. Sakamoto S, Kitahara S, Sumi S, Horiuchi S, Yoshida K. Relationship of epidermal growth factor binding capacity to histopathologic features and prognosis in human renal cell carcinoma. Invasion Metastasis 1997;17(2):94-100.
52. Hofmockel G, Riess S, Bassukas ID, Dammrich J. Epidermal growth factor family and renal cell carcinoma : expression and prognostic impact. Eur Urol 1997;31:476-84.
53. Hofmockel G, Bassukas ID, Wittmann A, Dammrich J. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? Br J Urol 1997;80:11-7.
54. Fujita K, Denda K, Yamamoto M, Matsumoto T, Fujime M, Irimura T. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer 1999;80(1-2):301-8.
55. Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991;15;51(14):3690-5.
56. Hofmann R, Lehmer A, Hartung R, Robrecht C, Bresch M, Grothe F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 1996;155:858-62.
57. Iwamura M, Wu W, Muramoto M, Ohori M, Egawa S. Uchida T et al. Parathyroid hormone-related protein is an independent prognostic factor for renal cell carcinoma. Cancer 1999;86(6):1028-34.
58. Tsui KH, Shvarts O, Smith RB, Figlin R, De Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000;163:426.
59. Lanigan D. Prognostic factors in renal cell carcinoma: BJU 1995;75:565-71.
60. Godley PA and Stinchcombe TE: Renal cell carcinoma. Curr Opin Oncol 1999;11:213-7.